Switch From Remicade to Celltrion’s Biosimilar CT-P13 Safe in IBD, Clinical Trial Concludes

Switch From Remicade to Celltrion’s Biosimilar CT-P13 Safe in IBD, Clinical Trial Concludes
Patients with inflammatory bowel disease (IBD) may safely switch from Remicade (infliximab) to its biosimilar version CT-P13 — sold as Remsima and Inflectra — according to recently published clinical trial results. Since many healthcare systems advocate switching to biosimilars because they're cheaper, these findings should go a long way in assuring patients and their physicians contemplating the switch. The study, “Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial,” appeared in The Lancet. Although its findings can be viewed as a victory for biosimilars, researchers stressed that the study pertains only to CT-P13, made by South Korea's Celltrion Healthcare. “The publication of the NOR-SWITCH data in The Lancet marks another important milestone on the path to increasing physician confidence in using biosimilar infliximab when looking to switch their patients,” a Celltron official said in a press release. Since no two antibodies are identical — even if they target the same structure — copies of biological drugs are called biosimilars. As biosimilar versions of biological drugs usually come with a cheaper price tag, it is common practice for healthcare systems to promote their use. But patients, stable on the original drug — and their physicians — might be reluct
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *